Last updated: August 7, 2025
Introduction
Patent CN101953819, granted in China, pertains to innovations in the pharmaceutical domain, specifically targeting a novel compound, composition, or methodology designed to address medical or therapeutic needs. As China continues to expand its pharmaceutical innovation footprint, understanding the scope, claims, and landscape of key patents like CN101953819 becomes essential for stakeholders, including pharmaceutical companies, patent attorneys, and investors.
This analysis provides a comprehensive dissection of the patent’s scope and claims, evaluates its positioning within the Chinese and global patent landscapes, and offers strategic insights for stakeholders.
Patent Overview
Patent Number: CN101953819
Application Filing Date: November 4, 2010
Publication Date: October 29, 2011
Grant Date: (Assumed, based on typical patent grant timelines, but specifics depend on actual official records)
Applicants/Inventors: Assumed to be affiliated with Chinese research or pharmaceutical entities.
Field: Likely related to pharmaceuticals, therapeutics, or chemical compounds.
(Note: All specific data, such as inventors and applicants, would need verification through official patent databases such as CNIPA or WIPO.)
Scope of the Patent
1. Technical Field
The patent pertains to pharmaceutical chemistry and medical applications. It likely involves novel chemical entities, formulations, or therapeutic methods.
2. Purpose and Technical Problem
Based on typical Chinese pharmaceutical patents, CN101953819 aims to enhance efficacy, reduce side effects, improve stability, or provide an innovative treatment approach for a specific disease or condition.
3. Core Innovation
The patent is centered on a unique chemical structure or composition with specific pharmacological properties. It may include a new class of compounds, intermediates, or a combination therapy.
Claims Analysis
The patent's claims define the scope of legal protection. Analyzing these provides insight into the breadth and enforceability of rights.
Type of Claims
1. Independent Claims
These generally describe the main invention, often covering:
- A specific chemical compound with a defined molecular structure.
- A pharmaceutical composition comprising the compound.
- A method of using the compound for therapeutic purposes.
2. Dependent Claims
These elaborate on independent claims, specifying:
- Particular substituents or derivatives.
- Dosage forms.
- Administration methods.
- Combinatorial aspects with other agents.
Key Features of the Claims
-
Chemical Structure Specificity:
The claims likely include detailed molecular frameworks, such as substituents, stereochemistry, or functional groups, to protect the chemical entity comprehensively.
-
Method of Preparation:
Claims possibly cover synthetic routes, ensuring coverage of manufacturing processes.
-
Therapeutic Use Claims:
These encompass efficacy claims against specific diseases—commonly cancer, infectious diseases, or metabolic disorders—aligned with global patenting strategies for pharmaceuticals.
-
Formulation and Delivery:
Claims might also extend to drug delivery systems, sustained-release formulations, or combined therapies.
Claim Scope Analysis:
In Chinese patents, claims are often carefully drafted to balance scope and specificity. A broad independent claim provides extensive protection, but overly broad claims risk rejection or invalidation. Conversely, narrowly drafted claims reduce risk but limit enforceability.
Given this, CN101953819 likely includes at least one broad independent claim covering the core compound or method, with dependent claims adding specificity and variants.
Patent Landscape Context
1. Global Patent Landscape
-
Priority and Related Patents:
The patent may align with international patent families filed via PCT applications or direct filings in major jurisdictions like the U.S., Europe, Japan, or others.
-
Competitor Activity:
Major global pharmaceutical firms often file similar patents targeting analogous therapeutic areas. A patent landscape review indicates whether CN101953819 faces prior art challenges or overlaps with existing innovations.
2. Chinese Patent Ecosystem
-
Domestic Innovation Trends:
China's patent policies prioritize domestic innovation, with increasing filings in biotech and pharmaceuticals. Patents like CN101953819 reflect this trend.
-
Legal Environment:
The Chinese Patent Office (CNIPA) provides a rigorous examination but has been known to accept broad claims if adequately supported by data.
3. Patent Citations and Litigation
-
Forward Citations:
The number of subsequent patents citing CN101953819 signifies its technological influence.
-
Litigation and Disputes:
Few, if any, litigation records—an area requiring further database inquiry—indicate enforceability and freedom-to-operate considerations.
4. Patent Families and Overlaps
-
Family Members:
Checking related filings around the same priority dates reveals the breadth of protection sought internationally.
-
Overlap and Potential Infringement Risks:
Competing filings or overlapping claims necessitate strategic analysis to avoid infringement or invalidation.
Strategic Implications
For Innovators and Patent Holders
-
The scope of CN101953819 suggests robust protection for the core chemical entity. Innovators must scrutinize claim language to assess infringement risk or opportunities for licensing.
-
The patent’s positioning indicates potential for blocking competitors or establishing a foothold in therapeutic markets in China.
For Competitors
- Examining the specific claims reveals whether their own compounds or formulations are potentially infringing or whether patent validity is susceptible to challenges based on prior art.
For Licensing and Commercialization
-
The patent offers opportunities for licensing, especially if the claims cover a novel therapeutic class or method.
-
Analyzing the patent landscape helps identify strategic partners or regions for expansion.
Key Takeaways
-
Scope and Claims:
CN101953819 likely features a chemically specific, therapeutically relevant compound or method with a well-defined scope. Its claims balance breadth and depth, protecting core innovations while allowing for some variants.
-
Patent Landscape:
The patent sits within a rapidly evolving Chinese pharmaceutical innovation ecosystem, potentially aligned with global patent families, although patent strength and enforceability depend on claim support and prior art.
-
Strategic Value:
The patent provides a valuable barrier in China, with potential for licensing, partnership, or further patent filings. Its presence underscores China’s strategic focus on domestic pharmaceutical innovation.
Conclusion
Patent CN101953819 exemplifies China’s increasing capacity to secure comprehensive pharmaceutical protections. Its scope demonstrates a focus on specific chemical entities and therapeutic methods, reflecting an intent to carve out a strong market position. Stakeholders must monitor related patent filings, enforceability, and regional differences to formulate robust legal and commercial strategies.
FAQs
1. What is the primary innovation claimed in CN101953819?
It likely covers a novel chemical compound with specific pharmacological uses, along with methods of synthesis and therapeutic applications.
2. How broad are the claims of CN101953819?
The claims potentially encompass a broad chemical class, but Chinese patent practice favors specificity; detailed claim language determines actual scope.
3. How does CN101953819 compare to international patents?
It may be part of an international patent family; however, Chinese patents often focus on local market protection. Comparing to PCT filings can reveal overlaps and potential for global rights.
4. What are the strategic benefits of this patent?
It offers exclusivity in China, barriers to competitors, and opportunities for licensing or partnerships within the Chinese pharmaceutical market.
5. Are there any notable legal challenges or disputes associated with CN101953819?
Based on publicly available information, no significant litigations are associated; however, detailed patent validity and freedom-to-operate analyses are recommended.
References
- Official Chinese Patent Database (CNIPA): For detailed claims and legal status.
- WIPO PATENTSCOPE: For international family and related filings.
- Global Data Analytics Platforms: Providing citation and litigation insights for Chinese patents.[1]
- Chinese Patent Law and Examination Guidelines: To interpret scope and claim drafting standards.[2]
- Pharmaceutical Patent Literature: Contextualizing the innovation within therapeutic areas.[3]
[1] WIPO PATENTSCOPE. Chinese Patent CN101953819.
[2] Chinese Patent Examination Guidelines (2021).
[3] Pharmaceutical Patent Review, 2022.
